Aliases & Classifications for Synovitis

MalaCards integrated aliases for Synovitis:

Name: Synovitis 12 75 53 55 44 15 17 72

Classifications:



External Ids:

Disease Ontology 12 DOID:2703
MeSH 44 D013585
NCIt 50 C50766
SNOMED-CT 68 14107000
UMLS 72 C0039103

Summaries for Synovitis

Disease Ontology : 12 A connective tissue disease that results in inflammation located in synovial membrane that lines a synovial joint which causes pain and swelling.

MalaCards based summary : Synovitis is related to noonan syndrome 1 and septic arthritis, and has symptoms including arthralgia, myalgia and metatarsalgia. An important gene associated with Synovitis is TNF (Tumor Necrosis Factor), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Etanercept and Prednisolone phosphate have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and bone marrow, and related phenotypes are cardiovascular system and growth/size/body region

Wikipedia : 75 Synovitis is the medical term for inflammation of the synovial membrane. This membrane lines joints that... more...

Related Diseases for Synovitis

Diseases related to Synovitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 649)
# Related Disease Score Top Affiliating Genes
1 noonan syndrome 1 33.1 TNF IL6 IL1B CXCL8
2 septic arthritis 31.5 MMP3 CXCL8 CRP
3 reactive arthritis 31.0 TNF CRP COMP
4 spondyloarthropathy 30.8 TNFSF11 TNF MMP3 IL6
5 sarcoidosis 1 30.7 TNF IL1B IL18 CD68
6 temporal arteritis 30.6 TNF IL6 IL1RN CRP
7 osteochondritis dissecans 30.5 MMP3 MMP13 COMP
8 spondylitis 30.5 TNF IL6 IL1RN CRP
9 palindromic rheumatism 30.5 TNF IL1B CRP
10 lyme disease 30.4 TNF IL6 IL1B CRP
11 chikungunya 30.4 TNF IL6 IL1B
12 angioimmunoblastic lymphadenopathy with dysproteinemia 30.4 TNF IL6
13 hemophilic arthropathy 30.4 TNFSF11 TNFRSF11B COMP
14 fasciitis 30.3 TNF IL6 IL18 CXCL8
15 osteomyelitis 30.3 TNFSF11 TNF IL6 IL1RN IL1B CXCL8
16 bronchiolitis obliterans 30.3 TNF IL6 CXCL8
17 pertussis 30.2 TNF IL6 IL1B
18 familial mediterranean fever 30.2 TNF IL1RN IL1B CRP
19 hydrarthrosis 30.2 MMP3 MMP13 IL1RN IL1B
20 gastritis 30.1 IL1RN IL1B CXCL8
21 end stage renal failure 30.1 TNF IL6 CRP
22 relapsing polychondritis 30.1 IL6 CRP COMP
23 exanthem 30.0 TNF IL6 IL1RN CRP
24 bone resorption disease 30.0 TNFSF11 TNFRSF11B IL6
25 juvenile rheumatoid arthritis 30.0 TNF IL6 IL1RN IL1B IL18 CRP
26 bronchitis 29.9 TNF CXCL8 CRP
27 osteoarthritis 29.9 TNF PRG4 MMP3 MMP13 MMP1 IL6
28 allergic rhinitis 29.8 VCAM1 IL18 ICAM1 CXCL8
29 bronchiolitis 29.8 TNF IL6 CXCL8 CRP
30 spondyloarthropathy 1 29.8 TNFRSF11B TNF MMP3 CRP CD163
31 cartilage disease 29.7 IL1RN CRP COMP
32 lymphadenitis 29.7 TNF IL1B IL18 ICAM1 CXCL8
33 pleurisy 29.7 TNF ICAM1 CXCL8 CRP
34 vasculitis 29.7 VCAM1 TNF SELE ICAM1 CRP
35 rheumatoid vasculitis 29.6 VCAM1 TNF SELE ICAM1
36 gastroenteritis 29.5 TNF IL6 IL1B CXCL8 CRP
37 inflammatory bowel disease 29.5 TNF IL6 IL1B IL18 CXCL8 CRP
38 pneumonia 29.5 TNF IL6 IL1B CXCL8 CRP
39 skin disease 29.4 TNF SELE ICAM1 CXCL8 CD163
40 peritonitis 29.4 TNF IL6 IL1B ICAM1 CXCL8 CRP
41 arthropathy 29.3 TNFSF11 TNFRSF11B TNF PRG4 CRP COMP
42 bacterial infectious disease 29.2 TNF IL6 IL1B IL18 CXCL8 CRP
43 kawasaki disease 29.2 TNF SELE MMP3 IL6 CRP
44 rheumatic disease 29.1 VCAM1 TNFRSF11B TNF IL1B IL18 CRP
45 arthritis 29.1 TNFSF11 TNF MMP3 MMP13 MMP1 IL6
46 multicentric reticulohistiocytosis 29.0 TNFSF11 TNFRSF11B
47 bone disease 28.7 TNFSF11 TNFRSF11B TNF MMP13 IL6 IL1B
48 systemic lupus erythematosus 28.5 VCAM1 TNF SELE IL6 IL1B IL18
49 pericarditis 28.3 TNF PRG4 IL6 IL1RN IL1B CRP
50 myeloma, multiple 28.2 TNFSF11 TNFRSF11B TNF IL6 CXCL8 CRP

Graphical network of the top 20 diseases related to Synovitis:



Diseases related to Synovitis

Symptoms & Phenotypes for Synovitis

UMLS symptoms related to Synovitis:


arthralgia, myalgia, metatarsalgia

MGI Mouse Phenotypes related to Synovitis:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.25 CD163 COMP CRP ICAM1 IL18 IL1B
2 growth/size/body region MP:0005378 10.15 COMP ICAM1 IL18 IL1B IL1RN IL6
3 cellular MP:0005384 10.14 CD163 COMP ICAM1 IL18 IL1RN IL6
4 hematopoietic system MP:0005397 10.13 CD163 CD68 ICAM1 IL18 IL1B IL1RN
5 homeostasis/metabolism MP:0005376 10.13 CD163 COMP CRP ICAM1 IL18 IL1B
6 immune system MP:0005387 10.06 CD163 CD68 COMP CRP ICAM1 IL18
7 integument MP:0010771 9.61 ICAM1 IL18 IL1B IL1RN IL6 MMP13
8 skeleton MP:0005390 9.32 CD68 COMP IL1B IL1RN IL6 MMP13

Drugs & Therapeutics for Synovitis

Drugs for Synovitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 184)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Etanercept Approved, Investigational Phase 4 185243-69-0
2
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
3
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Infliximab Approved Phase 4 170277-31-3
7
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
8
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
9
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 6221 5280795
10
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
11
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
12
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
13 Pharmaceutical Solutions Phase 4
14 Vitamins Phase 4
15 Hormones Phase 4
16 Methylprednisolone Acetate Phase 4
17 Neuroprotective Agents Phase 4
18 Prednisolone acetate Phase 4
19 Respiratory System Agents Phase 4
20 Cyclosporins Phase 4
21 Anti-Asthmatic Agents Phase 4
22 Betamethasone Valerate Phase 4 2152-44-5
23 Betamethasone sodium phosphate Phase 4
24 Betamethasone-17,21-dipropionate Phase 4
25 Calcineurin Inhibitors Phase 4
26 Betamethasone benzoate Phase 4
27 Calcium, Dietary Phase 4
28 Micronutrients Phase 4
29 Ergocalciferols Phase 4
30 Nutrients Phase 4
31 Vitamin D2 Phase 4
32 Trace Elements Phase 4
33 Calciferol Phase 4
34 Bone Density Conservation Agents Phase 4
35 Adrenocorticotropic Hormone Phase 4
36 beta-endorphin Phase 4
37 Melanocyte-Stimulating Hormones Phase 4
38
Adalimumab Approved Phase 3 331731-18-1 16219006
39
Abatacept Approved Phase 3 332348-12-6 10237
40
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
41
Sulfasalazine Approved Phase 3 599-79-1 5359476 5353980
42
Hydroxychloroquine Approved Phase 3 118-42-3 3652
43
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
44
Certolizumab pegol Approved Phase 3 428863-50-7
45
Tofacitinib Approved, Investigational Phase 3 477600-75-2
46
Colchicine Approved Phase 3 64-86-8 6167 2833
47
Sargramostim Approved, Investigational Phase 3 83869-56-1, 123774-72-1
48
Lidocaine Approved, Vet_approved Phase 3 137-58-6 3676
49
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
50
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743

Interventional clinical trials:

(show top 50) (show all 156)
# Name Status NCT ID Phase Drugs
1 Targeting Synovitis in Early Rheumatoid Arthritis (TaSER). Intensive Management of Early Rheumatoid Arthritis Using Either Clinical or Musculoskeletal Ultrasound Assessment of Synovitis − a Randomised Study With Blinded Outcome Assessments Unknown status NCT00920478 Phase 4
2 Remission Induction in Very Early Rheumatoid Arthritis: a Comparison of Etanercept Plus Methotrexate Plus Steroid With Standard Therapy Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
3 A Multicentre Randomised Trial Of Etanercept And Methotrexate To Induce Remission In Early Inflammatory Arthritis Unknown status NCT01303874 Phase 4 Etanercept (ETN);Placebo
4 A Randomized, Double-blind Study to Evaluate the Efficacy of Iguratimod Versus Placebo in Patients With Rheumatoid Arthritis on Magnetic Resonance Imaging (MRI) Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
5 The Comparative Study of Safety and Effectiveness of Intra-articular Injection of Tocilizumab and Compound Betamethasone in Rheumatoid Arthritis of the Knee Unknown status NCT03215407 Phase 4 Intra-articular Tocilizumab;Intra-articular Compound Betamethasone
6 Phase IV Study of Early RA: a Randomized Magnetic Resonance Imaging Study Comparing the Effects of Methotrexate Alone or in Combination With Infliximab or Intravenous Pulse Methylprednisolone Completed NCT00396747 Phase 4 Infliximab, methylprednisolone, methotrexate;Methotrexate;Methotrexate + Methylprednisolone;Methotrexate + Infliximab
7 Combination Treatment With Methotrexate and Cyclosporine in Early Rheumatoid Arthritis. Completed NCT00209859 Phase 4 Methotrexate;Intraarticular betamethasone;Cyclosporine/placebo-cyclosporine
8 Pilot Study to Evaluate the Effect of Mabthera in Combination With MTX in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis. Completed NCT00502853 Phase 4 rituximab [MabThera/Rituxan];Methotrexate
9 Musculoskeletal Ultrasound in Predicting Early Dose Titration With Tocilizumab Completed NCT01717859 Phase 4 Tocilizumab
10 Phase 4 Study of Low Dose Prednisolone for Knee Osteoarthritis Completed NCT01619163 Phase 4 Placebo;Prednisolone
11 Study of The Effect of Corticotrophin in Combination With Methotrexate in Newly Diagnosed Rheumatoid Arthritis Patients From a Clinical and Structural Perspective As Measured by a Clinical Disease Activity Index Score and Bone Edema, Synovitis and Erosions on Magnetic Resonance Imaging Completed NCT01948388 Phase 4 corticotrophin 80 units
12 Aiming for Remission in Rheumatoid Arthritis: a Randomized Trial Examining the Benefit of Ultrasonography in a Clinical TIght Control Regimen Completed NCT01205854 Phase 4
13 A Randomized, Double-blind, Placebo-controlled Study to Assess Efficacy of Tocilizumab+Non-biological DMARD in Reducing Synovitis as Measured by MRI at 12 Weeks After Initiation of Treatment in Patients With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Non-biological DMARDs Completed NCT01034397 Phase 4 tocilizumab [RoActemra/Actemra];placebo;non-biological DMARDs
14 Can Bone Erosions Heal in Adalimumab (Humira) Treated Rheumatoid Arthritis Patients. An Imaging Study Using Computed Tomography and Magnetic Resonance Imaging. Completed NCT00696059 Phase 4 Adalimumab (Humira)
15 Randomized Clinical Evaluation of Bone Mineral Density Changes Under Non-cemented Trabecular Metal Tibial Component and Cemented Titanium Controls. Completed NCT01764984 Phase 4
16 Randomized, Double-blind, Placebo-controlled Trial to Measure the Efficacy and Safety of Vitamin D3 in Patients With Fibromyalgia. Completed NCT03369379 Phase 4 D3 Vitamin
17 Use of Acthar in Rheumatoid Arthritis Related Flares Recruiting NCT02541955 Phase 4 Acthar
18 Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS) Recruiting NCT03419650 Phase 4 ACTHar
19 Dosing of Intra-articular Triamcinolone Hexacetonide for Knee Synovitis in Chronic Polyarthritis Active, not recruiting NCT02437461 Phase 4 Triamcinolone hexacetonide
20 Adipose Derived Stromal Cell Transplantation as an Adjunct to Arthroscopy in Treatment of Effusion Synovitis of the Early Degenerative Knee Not yet recruiting NCT03922490 Phase 4
21 Open Label Study to Describe the Effect of Tocilizumab in Combination With MTX in the Evolution of Articular Damage (Synovitis/Osteitis and Erosions) Evaluated by MRI in the Hand of Patients With Moderate to Severe Rheumatoid Arthritis (RA) and Inadequate Response to Non-biological DMARDs Withdrawn NCT01878318 Phase 4 methotrexate;tocilizumab [RoActemra/Actemra]
22 A Phase 3, Multicenter, Randomized, Open, Prospective, Controlled, Parallel Group Study of Reduction of Therapy in Patients With Rheumatoid Arthritis in Ongoing Remission. Unknown status NCT02779114 Phase 3 Control group
23 Study of the Effect of Chondroitin Sulphate on Synovial Inflammation in Patients With Osteoarthritis of the Knee Completed NCT00604539 Phase 3 Chondroitin sulphate (Condrosan);Placebo
24 Intra-Articular Injection of Etanercept in Patient Suffering From Rheumatoid Arthritis : a Double-Blind Randomized Study for Evaluation of Efficacy and Safety of Etanercept Versus Intra-Articular Steroid Injection in Acute Synovitis Completed NCT00522184 Phase 3
25 The Effect of Certolizumab Pegol in Combination With Methotrexate on MRI Synovitis and Bone Edema and Patient Reported Outcomes as Measured Using an Automated Visit Manager System in Moderate to Severe Rheumatoid Arthritis Patients Completed NCT01213017 Phase 3 certolizumab pegol
26 A Phase IIIB Multicenter, Randomized, Double-Blind, Placebo-controlled Study to Assess Short-term Changes in Synovitis and Structural Damage Outcomes in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate, Treated With Abatacept Versus Placebo on a Background Therapy With Methotrexate Completed NCT00420199 Phase 3 Abatacept;Placebo
27 A 16-week Double-blind, Placebo-controlled (for Initial 2 Weeks) Randomized Period, Followed by a 24-week Open-label Extension to Assess Magnetic Resonance Image (MRI) - Verified Early Response to Certolizumab Pegol in Subjects With Active Rheumatoid Arthritis (RA) Completed NCT01235598 Phase 3
28 An Evaluation of the Optimal Dose of Tofacitinib Needed to Achieve LDA or Clinical Remission in Patients With Active Rheumatoid Arthritis (RA) as Measured From a Clinical and Structural Perspective When Treating to Target Completed NCT02566967 Phase 3 tofacitinib
29 DOES ETANERCEPT INFLUENCE TWEAK MODULATION OF INFLAMMATION DURING INFLAMMATORY RHEUMATISMS (PSORIATIC ARTHRITIS AND RHEUMATOID ARTHRITIS)? Completed NCT02164214 Phase 3 etanercept Treatment
30 Open Label, Multicentric Phase IIIb Study to Evaluate the Effect of Tocilizumab in Combination With DMARDs in the Inhibition of Progression of Synovitis, Bone Marrow Edema, and Erosions Evaluated by Dedicated Magnetic Resonance Imaging (MRI) in the Hand of Patients With Rheumatoid Arthritis (RA) Completed NCT00996606 Phase 3 DMARDs;Tocilizumab
31 A Randomized Placebo-Controlled Study of the Efficacy and Safety of Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever Completed NCT01705756 Phase 3 Kineret
32 Evaluation of Rituximab in Systemic Sclerosis Associated Polyarthritis Completed NCT01748084 Phase 2, Phase 3 Rituximab;Placebo (NaCl)
33 A 52-week, Multicenter Study to Assess the Time Course of Response to Secukinumab on Joint Inflammation Using Power Doppler Ultrasonography in Patients With Active Psoriatic Arthritis Recruiting NCT02662985 Phase 3 AIN457 (secukinumab);Placebo
34 Ultrasound Scores as Imaging Biomarkers of Early Response to Subcutaneous Tocilizumab in Association With Methotrexate in Very Early Rheumatoid Arthritis (TOVERA) Recruiting NCT02837146 Phase 3 Methotrexate (MTX)
35 A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath Active, not recruiting NCT02371369 Phase 3 Pexidartinib;Placebo
36 Multicentre Canadian Study to Measure the Safety and Efficacy of Synoviorthesis Performed With Yttrium-90 or Rhenium-186 Sulfide Active, not recruiting NCT01615991 Phase 3 Radiosynoviorthesis
37 A Phase 3, Multicenter, 12-Week, Double-Blind and 40-Week Open Label Study to Evaluate the Efficacy and Safety of X0002 Spray in Relief of the Signs and Symptoms of Subjects With Osteoarthritis of the Knee Not yet recruiting NCT03081806 Phase 3 X0002
38 A Double-blinded, Prospective, Randomized, Controlled Trial Comparing Dexamethasone Versus Ketorolac Injection for the Treatment of Local Inflammatory Hand and Upper Extremity Disorders Terminated NCT02266433 Phase 3 Ketorolac;Dexamethasone
39 Knee Osteoarthritis AND Methotrexate Use Unknown status NCT01927484 Phase 2 25 mg/week oral methotrexate tablets;25mg/week oral placebo tablets
40 Evaluation of Inflammatory and Structural Joint Damage in Patients With Psoriasis and Psoriatic Arthritis Treated With Secukinumab: A Phase 2, Single Arm, Single Centre Mode of Action Study (Psoriasis-Arthritis & Bone Program, PSARTROS) Unknown status NCT02483234 Phase 2 secukinumab
41 Chronic Non-bacterial Osteomyelitis Treated With Pamidronate in a Randomised Placebo Controlled Trial Unknown status NCT02594878 Phase 2 Pamidronatdinatrium
42 A Phase II Randomized, Double -Blind, Placebo Controlled Study to Assess Safety, Tolerability and Effect on Tumor Size of MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) Completed NCT01643850 Phase 2 MCS110;Placebo;MCS110;Placebo
43 A Prospective Double-Blinded Clinical Trial Using Apatone®B for Care and Treatment of Proven Non-Infected Symptomatic Postoperative Total Joint Arthroplasties Completed NCT01272830 Phase 2 Placebo;Apatone®B
44 A Phase 2a Study Evaluating the Safety, Efficacy, and Pharmacodynamic Effects of ABT-981 in Patients With Knee Osteoarthritis Completed NCT02087904 Phase 2
45 Phase II Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT) Completed NCT01261429 Phase 2 Tasigna
46 Evaluation of The Efficacy And Safety of Intra-Articular Etanercept in Patients With Refractory Knee Joint Synovitis: a Placebo Controlled, Single-Blind, Crossover-Trial, With Randomisation of Treatment Sequence Completed NCT00678782 Phase 2 etanercept;placebo
47 Methotrexate Alone Versus Combination of Methotrexate and Subcutaneous Fludarabine for Severe Rheumatoid Arthritis: Safety, Tolerance and Efficacy Completed NCT00001677 Phase 2 Methotrexate;Fludarabine
48 Monoarticular Corticosteroid Injection Versus Systemic Administration in the Treatment of Rheumatoid Arthritis Patients: A Randomized Double-Blind Controlled Study Completed NCT00506896 Phase 2 intraarticular injection
49 Impact of Rituximab on Magnetic Resonance Imaging Evidence of Synovitis and Bone Lesions in Patients With Moderate or Severe Rheumatoid Arthritis Completed NCT00425932 Phase 2
50 MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE Recruiting NCT03355482 Phase 2 Methylprednisolone;Placebos

Search NIH Clinical Center for Synovitis

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Bupivacaine
Cortisone acetate
Dexamethasone
Hydrocortisone
Methylprednisolone
Prednisolone
Triamcinolone

Cochrane evidence based reviews: synovitis

Genetic Tests for Synovitis

Anatomical Context for Synovitis

MalaCards organs/tissues related to Synovitis:

41
Bone, T Cells, Bone Marrow, Endothelial, B Cells, Neutrophil, Skin

The Foundational Model of Anatomy Ontology organs/tissues related to Synovitis:

19
Synovial Membrane

Publications for Synovitis

Articles related to Synovitis:

(show top 50) (show all 10392)
# Title Authors PMID Year
1
Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides. 9 38
20436079 2010
2
TNF-alpha-induced aquaporin 9 in synoviocytes from patients with OA and RA. 9 38
20181673 2010
3
Haem oxygenase-1 down-regulates high mobility group box 1 and matrix metalloproteinases in osteoarthritic synoviocytes. 9 38
20110250 2010
4
Expression of aquaporin 1 (AQP1) in human synovitis. 9 38
20149606 2010
5
Immunologic rheumatic disorders. 9 38
20176259 2010
6
c-Fms-mediated differentiation and priming of monocyte lineage cells play a central role in autoimmune arthritis. 9 38
20181277 2010
7
Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. 9 38
19565512 2009
8
Interleukin-6 as a key player in systemic inflammation and joint destruction. 9 38
19189867 2009
9
Absence of a classically activated macrophage cytokine signature in peripheral spondylarthritis, including psoriatic arthritis. 9 38
19333931 2009
10
[Content of C-reactive protein, interleukin-1, interleukin-6 and interleukin-1 receptor antagonist in the blood of patients with early osteoarthrosis of the knee joints]. 9 38
19663194 2009
11
Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. 9 38
18762862 2009
12
Adiponectin may contribute to synovitis and joint destruction in rheumatoid arthritis by stimulating vascular endothelial growth factor, matrix metalloproteinase-1, and matrix metalloproteinase-13 expression in fibroblast-like synoviocytes more than proinflammatory mediators. 9 38
19883500 2009
13
Identification of interleukin-7 as a candidate disease mediator in spondylarthritis. 9 38
18975340 2008
14
Association of body fat with C-reactive protein in rheumatoid arthritis. 9 38
18759279 2008
15
Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? 9 38
18234715 2008
16
Measurement of biomarkers in juvenile idiopathic arthritis patients and their significant association with disease severity: a comparative study. 9 38
18578976 2008
17
Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature. 9 38
17976692 2008
18
Involvement of TWEAK/Fn14 interaction in the synovial inflammation of RA. 9 38
18310134 2008
19
Imbalanced expression of RANKL and osteoprotegerin mRNA in pannus tissue of rheumatoid arthritis. 9 38
18565244 2008
20
The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. 9 38
18311801 2008
21
Induction of macrophage secretion of tumor necrosis factor alpha through Fcgamma receptor IIa engagement by rheumatoid arthritis-specific autoantibodies to citrullinated proteins complexed with fibrinogen. 9 38
18311806 2008
22
Anti-inflammatory activity of chondroitin sulfate. 9 38
18667340 2008
23
[Cartilage oligomeric matrix protein, a possible marker of synovitis in early knee joint osteoarthrosis]. 9 38
19177799 2008
24
Induction of arthritis by high mobility group box chromosomal protein 1 is independent of tumour necrosis factor signalling. 9 38
18582368 2008
25
Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study. 9 38
18346273 2008
26
Bone edema determined by magnetic resonance imaging reflects severe disease status in patients with early-stage rheumatoid arthritis. 9 38
17918786 2007
27
Expression of receptor activator of nuclear factor-kappaB ligand in synovial tissue: comparison with degradation of articular cartilage in temporomandibular joint disorders. 9 38
17560137 2007
28
[Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein]. 9 38
17642234 2007
29
Serum levels of matrix metalloproteinase 3 (stromelysin 1) for monitoring synovitis in rheumatoid arthritis. 9 38
17425385 2007
30
Toll-like receptor 2 and 4 combination engagement upregulate IL-15 synergistically in human rheumatoid synovial fibroblasts. 9 38
17289161 2007
31
Morphological characterization of intra-articular HMGB1 expression during the course of collagen-induced arthritis. 9 38
17397533 2007
32
Comparison of taurine chloramine and taurine bromamine effects on rheumatoid arthritis synoviocytes. 9 38
16868648 2007
33
Bone oedema predicts erosive progression on wrist MRI in early RA--a 2-yr observational MRI and NC scintigraphy study. 9 38
16670155 2006
34
Inflammation-induced bone loss: can it be prevented? 9 38
17288976 2006
35
Pathogenesis of spondyloarthritis: insights from synovial membrane studies. 9 38
16839506 2006
36
Changes in MMP-2 and -9 activity and MMP-8 reactivity after amphotericin B induced synovitis and treatment with bufexamac. 9 38
16901276 2006
37
The expression of collagenase 3 (MMP-13) mRNA in the synovial tissue is associated with histopathologic type II synovitis in rheumatoid arthritis. 9 38
16891219 2006
38
Anti-TNF and sex hormones. 9 38
16855166 2006
39
Synovial proinflammatory cytokines and their correlation with matrix metalloproteinase-3 expression in Behçet's disease. Does interleukin-1beta play a major role in Behçet's synovitis? 9 38
16205926 2006
40
Decrease in expression of bone morphogenetic proteins 4 and 5 in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. 9 38
16542506 2006
41
The role of synovial macrophages and macrophage-produced cytokines in driving aggrecanases, matrix metalloproteinases, and other destructive and inflammatory responses in osteoarthritis. 9 38
17177994 2006
42
Different ELR (+) angiogenic CXC chemokine profiles in synovial fluid of patients with Behçet's disease, familial Mediterranean fever, rheumatoid arthritis, and osteoarthritis. 9 38
15672235 2005
43
Changes of cartilage and bone markers after intra-articular glucocorticoid treatment with and without postinjection rest in patients with rheumatoid arthritis. 9 38
15843449 2005
44
Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. 9 38
16329106 2005
45
Targeting cytokines beyond tumor necrosis factor-alpha and interleukin-1 in rheumatoid arthritis. 9 38
16282041 2005
46
Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. 9 38
16076882 2005
47
Immunoglobulin G from anti-glucose-6-phosphate isomerase antibodies positive patient with rheumatoid arthritis induces synovitis in cynomolgus monkeys. 9 38
16137614 2005
48
Histological patterns of synovitis and serum chemokines in patients with rheumatoid arthritis. 9 38
16142858 2005
49
Targeting interleukin-15 in patients with rheumatoid arthritis: a proof-of-concept study. 9 38
16142748 2005
50
Tumor necrosis factor-alpha increases chemokine gene expression and production in synovial fibroblasts from human temporomandibular joint. 9 38
15946184 2005

Variations for Synovitis

Expression for Synovitis

Search GEO for disease gene expression data for Synovitis.

Pathways for Synovitis

Pathways related to Synovitis according to GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.05 VCAM1 TNFSF11 TNFRSF11B TNF PRSS2 MMP3
2
Show member pathways
13.38 VCAM1 TNFSF11 TNFRSF11B TNF MMP3 MMP1
3
Show member pathways
12.93 TNF IL6 IL1B IL18 ICAM1 CXCL8
4
Show member pathways
12.82 VCAM1 PRSS2 MMP3 MMP13 MMP1 ICAM1
5
Show member pathways
12.8 TNF IL6 IL1B IL18 CXCL8
6 12.62 VCAM1 TNFSF11 TNF IL1RN IL1B
7
Show member pathways
12.44 VCAM1 TNFSF11 TNFRSF11B ICAM1
8
Show member pathways
12.4 TNF IL6 IL1B ICAM1 CRP
9
Show member pathways
12.4 TNF MMP3 MMP13 MMP1 IL6 IL1B
10 12.38 VCAM1 TNF IL6 ICAM1
11
Show member pathways
12.33 TNF IL6 IL1B CXCL8
12
Show member pathways
12.31 TNF IL6 IL1B IL18 CXCL8
13
Show member pathways
12.31 VCAM1 PRG4 MMP3 MMP13 MMP1 IL1B
14
Show member pathways
12.3 TNF IL6 IL1RN IL1B IL18 CXCL8
15
Show member pathways
12.29 TNFSF11 MMP3 MMP13 MMP1
16 12.28 TNF IL6 IL1B IL18
17 12.25 TNF IL6 IL1RN IL1B CXCL8
18
Show member pathways
12.24 TNF IL6 IL1B CXCL8
19 12.18 VCAM1 TNF SELE IL1B ICAM1
20
Show member pathways
12.13 IL6 IL1B IL18 ICAM1 CXCL8
21
Show member pathways
12.13 TNF PRSS2 MMP3 IL6 IL1B
22
Show member pathways
12.11 TNF IL6 IL1B IL18
23 12.1 TNFSF11 TNFRSF11B TNF IL1B
24 12.1 TNF IL6 IL1B ICAM1 CXCL8
25 12.08 VCAM1 MMP3 MMP13 ICAM1
26 12.07 VCAM1 TNF SELE MMP3 IL6 IL1B
27 12.05 TNF IL6 CD68 CD163
28
Show member pathways
12.01 TNF PRSS2 MMP3 MMP13 MMP1
29 12 VCAM1 TNFSF11 TNF IL1B ICAM1 CXCL8
30 11.98 TNF IL6 IL1B CXCL8
31 11.98 VCAM1 TNF SELE IL6 IL1B ICAM1
32 11.97 VCAM1 TNF MMP3 MMP1 IL6 IL1B
33 11.9 SELE MMP1 IL6 ICAM1 CXCL8
34
Show member pathways
11.89 IL6 ICAM1 CXCL8
35 11.88 IL6 IL1B IL18 CXCL8
36
Show member pathways
11.85 TNFSF11 IL6 CRP
37 11.84 TNF IL6 IL1B CXCL8
38 11.83 TNF IL6 IL1B CD163
39 11.81 TNF IL1B IL18
40 11.78 TNFSF11 TNF MMP3 MMP1 IL6 IL1B
41 11.77 TNF MMP3 IL6 IL1RN IL1B IL18
42 11.76 TNF IL6 IL1B CXCL8
43 11.74 MMP3 MMP13 MMP1 CXCL8
44 11.69 TNF IL6 IL1B IL18 CXCL8
45 11.64 SELE IL6 CXCL8
46 11.64 TNF IL6 IL1RN IL1B IL18 ICAM1
47 11.61 MMP1 IL6 CXCL8
48 11.59 TNFSF11 TNFRSF11B TNF IL6 IL1B
49 11.58 TNF IL1B IL18
50 11.57 TNF IL6 ICAM1

GO Terms for Synovitis

Cellular components related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.86 TNFSF11 TNFRSF11B TNF PRSS2 PRG4 MMP3
2 extracellular matrix GO:0031012 9.63 TNFRSF11B PRSS2 MMP3 MMP13 MMP1 COMP
3 extracellular space GO:0005615 9.53 VCAM1 TNFSF11 TNFRSF11B TNF SELE PRSS2

Biological processes related to Synovitis according to GeneCards Suite gene sharing:

(show top 50) (show all 52)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of I-kappaB kinase/NF-kappaB signaling GO:0043123 9.98 TNFSF11 TNF IL1RN IL1B
2 response to lipopolysaccharide GO:0032496 9.97 VCAM1 SELE IL1B ICAM1
3 extracellular matrix organization GO:0030198 9.96 VCAM1 TNFRSF11B TNF ICAM1 COMP
4 leukocyte migration GO:0050900 9.93 TNF SELE MMP1 IL1B ICAM1
5 immune response GO:0006955 9.92 TNFSF11 TNF PRG4 IL6 IL1RN IL1B
6 positive regulation of DNA-binding transcription factor activity GO:0051091 9.9 TNFSF11 TNF IL6 IL1B
7 calcium-mediated signaling GO:0019722 9.89 TNFSF11 SELE CXCL8
8 neutrophil chemotaxis GO:0030593 9.88 IL1RN IL1B CXCL8
9 tumor necrosis factor-mediated signaling pathway GO:0033209 9.87 TNFSF11 TNFRSF11B TNF
10 cellular response to organic cyclic compound GO:0071407 9.87 TNF IL1B IL18
11 positive regulation of T cell proliferation GO:0042102 9.87 VCAM1 IL6 IL1B
12 positive regulation of JNK cascade GO:0046330 9.87 TNFSF11 TNF IL1RN IL1B
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.86 TNF IL6 IL18
14 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.85 TNF IL1B IL18
15 cellular response to lipopolysaccharide GO:0071222 9.85 TNF IL6 IL1RN IL1B ICAM1 CXCL8
16 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules GO:0007157 9.82 VCAM1 SELE ICAM1
17 positive regulation of interferon-gamma production GO:0032729 9.82 TNF IL1B IL18
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.81 TNF IL1B ICAM1
19 extracellular matrix disassembly GO:0022617 9.8 PRSS2 MMP3 MMP13 MMP1
20 acute-phase response GO:0006953 9.79 IL6 CRP CD163
21 lipopolysaccharide-mediated signaling pathway GO:0031663 9.79 TNF IL1B IL18
22 positive regulation of interleukin-6 production GO:0032755 9.78 TNF IL6 IL1RN IL1B
23 leukocyte cell-cell adhesion GO:0007159 9.77 VCAM1 SELE ICAM1
24 negative regulation of neurogenesis GO:0050768 9.76 TNF IL6 IL1B
25 collagen catabolic process GO:0030574 9.73 PRSS2 MMP3 MMP13 MMP1
26 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.73 TNFSF11 TNF IL6 IL1B IL18 ICAM1
27 leukocyte tethering or rolling GO:0050901 9.72 VCAM1 TNF SELE
28 negative regulation of bone resorption GO:0045779 9.71 TNFRSF11B IL6
29 positive regulation of granulocyte macrophage colony-stimulating factor production GO:0032725 9.71 IL1B IL18
30 neutrophil activation GO:0042119 9.7 IL18 CXCL8
31 growth plate cartilage development GO:0003417 9.7 MMP13 COMP
32 positive regulation of glial cell proliferation GO:0060252 9.7 TNF IL6 IL1B
33 positive regulation of chemokine biosynthetic process GO:0045080 9.69 TNF IL1B
34 regulation of establishment of endothelial barrier GO:1903140 9.69 TNF IL1B
35 response to glucocorticoid GO:0051384 9.69 TNF IL6 IL1RN
36 interleukin-6 production GO:0032635 9.68 IL1B IL18
37 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.68 TNF ICAM1
38 response to hypoxia GO:0001666 9.67 VCAM1 ICAM1
39 positive regulation of T-helper 1 cell cytokine production GO:2000556 9.66 IL1B IL18
40 positive regulation of fever generation GO:0031622 9.66 TNF IL1B
41 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.65 IL6 IL1RN
42 membrane to membrane docking GO:0022614 9.65 VCAM1 ICAM1
43 regulation of cell adhesion GO:0030155 9.63 IL18 CXCL8
44 sequestering of triglyceride GO:0030730 9.63 TNF IL1B
45 negative regulation of lipid storage GO:0010888 9.63 TNF IL6 CRP
46 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.61 TNF IL1B
47 inflammatory response GO:0006954 9.61 TNF SELE IL6 IL1RN IL1B IL18
48 positive regulation of neuroinflammatory response GO:0150078 9.46 TNF IL6 IL1B IL18
49 cytokine-mediated signaling pathway GO:0019221 9.36 VCAM1 TNFSF11 TNF MMP3 MMP1 IL6
50 positive regulation of JUN kinase activity GO:0043507 9.32 TNF

Molecular functions related to Synovitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 serine-type endopeptidase activity GO:0004252 9.33 PRSS2 MMP3 MMP1
2 cytokine activity GO:0005125 9.23 TNFSF11 TNFRSF11B TNF IL6 IL1RN IL1B
3 metalloendopeptidase activity GO:0004222 9.13 MMP3 MMP13 MMP1

Sources for Synovitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....